NCT06008756: Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
- State
- Under way
- Phase
- Phase 3
- People
- 14,550 planned
- Started
- 9 Oct 2023
- Primary completion
- 29 Nov 2029
- Arms
- Blinded Portion: Enlicitide Decanoate, Open-Label Extension: Enlicitide Decanoate
- Results
- None posted
- 24 Aug 2023: Trial registered
- 9 Oct 2023: Trial started